Potential role for ET-2 acting through ETA receptors in experimental colitis in mice
- PMID: 27778057
- DOI: 10.1007/s00011-016-1001-7
Potential role for ET-2 acting through ETA receptors in experimental colitis in mice
Abstract
Objective and design: This study attempted to clarify the roles of endothelins and mechanisms associated with ETA/ETB receptors in mouse models of colitis.
Materials and methods: Colitis was induced by intracolonic administration of 2,4,6-trinitrobenzene sulfonic acid (TNBS, 1.5 mg/animal) or dextran sulfate sodium (DSS, 3%). After colitis establishment, mice received Atrasentan (ETA receptor antagonist, 10 mg/kg), A-192621 (ETB receptor antagonist, 20 mg/kg) or Dexamethasone (1 mg/kg) and several inflammatory parameters were assessed, as well as mRNA levels for ET-1, ET-2 and ET receptors.
Results: Atrasentan treatment ameliorates TNBS- and DSS-induced colitis. In the TNBS model was observed reduction in macroscopic and microscopic score, colon weight, neutrophil influx, IL-1β, MIP-2 and keratinocyte chemoattractant (KC) levels, inhibition of adhesion molecules expression and restoration of IL-10 levels. However, A192621 treatment did not modify any parameter. ET-1 and ET-2 mRNA was decreased 24 h, but ET-2 mRNA was markedly increased at 48 h after TNBS. ET-2 was able to potentiate LPS-induced KC production in vitro. ETA and ETB receptors mRNA were increased at 24, 48 and 72 h after colitis induction.
Conclusions: Atrasentan treatment was effective in reducing the severity of colitis in DSS- and TNBS-treated mice, suggesting that ETA receptors might be a potential target for inflammatory bowel diseases.
Keywords: 2,4,6-Trinitrobenzene sulfonic acid; Colitis; Dextran sulfate sodium; Endothelins.
Similar articles
-
Novel anti-inflammatory agent 3-[(dodecylthiocarbonyl)-methyl]-glutarimide ameliorates murine models of inflammatory bowel disease.Inflamm Res. 2016 Mar;65(3):245-60. doi: 10.1007/s00011-015-0911-0. Epub 2015 Dec 18. Inflamm Res. 2016. PMID: 26683259
-
Endothelins implicated in referred mechanical hyperalgesia associated with colitis induced by TNBS in mice.Can J Physiol Pharmacol. 2010 Jun;88(6):661-7. doi: 10.1139/Y10-043. Can J Physiol Pharmacol. 2010. PMID: 20628432
-
The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment.Inflamm Bowel Dis. 2011 Aug;17(8):1651-64. doi: 10.1002/ibd.21538. Epub 2010 Nov 15. Inflamm Bowel Dis. 2011. PMID: 21744421 Free PMC article.
-
Role of the endothelin axis and its antagonists in the treatment of cancer.Br J Pharmacol. 2011 May;163(2):220-33. doi: 10.1111/j.1476-5381.2011.01217.x. Br J Pharmacol. 2011. PMID: 21232046 Free PMC article. Review.
-
Critical appraisal of the current practice in murine TNBS-induced colitis.Inflamm Bowel Dis. 2006 Oct;12(10):995-9. doi: 10.1097/01.mib.0000227817.54969.5e. Inflamm Bowel Dis. 2006. PMID: 17012970 Review.
Cited by
-
Pathological angiogenesis and inflammation in tissues.Arch Pharm Res. 2021 Jan;44(1):1-15. doi: 10.1007/s12272-020-01287-2. Epub 2020 Nov 23. Arch Pharm Res. 2021. PMID: 33230600 Free PMC article. Review.
-
Treatment With Endothelin-A Receptor Antagonist BQ123 Attenuates Acute Inflammation in Mice Through T-Cell-Dependent Polymorphonuclear Myeloid-Derived Suppressor Cell Activation.Front Immunol. 2021 Mar 22;12:641874. doi: 10.3389/fimmu.2021.641874. eCollection 2021. Front Immunol. 2021. PMID: 33828553 Free PMC article.
-
Exploring the pivotal role of endothelin in rheumatoid arthritis.Inflammopharmacology. 2022 Oct;30(5):1555-1567. doi: 10.1007/s10787-022-01051-6. Epub 2022 Aug 27. Inflammopharmacology. 2022. PMID: 36029362 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources